Berlin - Delayed Quote • EUR Genenta Science SPA (K5F.BE) Follow Compare 4.8200 -0.0800 (-1.63%) At close: January 10 at 9:40:06 PM GMT+1 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for K5F.BE 1D 5D 7.11% 1M -1.63% 3M -22.26% 6M 59.60% YTD 3.88% 1Y 10.55% 5Y -51.80% All -51.80% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: K5F.BE View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Genenta Science announces amendment to pact with AGC Biologics Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE 3 US Penny Stocks With Market Caps Over $30M To Consider Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer Genenta Science S.p.A. (GNTA): Early Investment Opportunity in Innovative Biotech 7 Penny Biotech Stocks to Triple Your Investment Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors